CONTEXTLOGIC INC - A (LOGC)

US21077C3051 - Common Stock

5.48  -0.05 (-0.9%)

After market: 5.3803 -0.1 (-1.82%)

Fundamental Rating

1

LOGC gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 587 industry peers in the Biotechnology industry. LOGC has a bad profitability rating. Also its financial health evaluation is rather negative. LOGC is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

LOGC had negative earnings in the past year.
In the past year LOGC has reported a negative cash flow from operations.
LOGC had negative earnings in each of the past 5 years.
In the past 5 years LOGC always reported negative operating cash flow.

1.2 Ratios

Industry RankSector Rank
ROA -68.77%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -240.64%
PM (TTM) -246.71%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

1

2. Health

2.1 Basic Checks

LOGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LOGC has more shares outstanding
Compared to 1 year ago, LOGC has a worse debt to assets ratio.

2.2 Solvency

LOGC has an Altman-Z score of -5.35. This is a bad value and indicates that LOGC is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of 0.17 indicates that LOGC is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Altman-Z -5.35
ROIC/WACCN/A
WACC9.93%

2.3 Liquidity

A Current Ratio of 1.99 indicates that LOGC should not have too much problems paying its short term obligations.
LOGC has a Quick Ratio of 1.99. This is a normal value and indicates that LOGC is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.99
Quick Ratio 1.99

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 31.36% over the past year.
LOGC shows a strong growth in Revenue. In the last year, the Revenue has grown by 174.32%.
EPS 1Y (TTM)31.36%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q41.94%
Revenue 1Y (TTM)174.32%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q28.16%

3.2 Future

The Earnings Per Share is expected to grow by 6.59% on average over the next years.
The Revenue is expected to grow by 95.41% on average over the next years. This is a very strong growth
EPS Next Y34.6%
EPS Next 2Y12.97%
EPS Next 3Y12.15%
EPS Next 5Y6.59%
Revenue Next Year144.21%
Revenue Next 2Y-31.27%
Revenue Next 3Y66.92%
Revenue Next 5Y95.41%

3.3 Evolution

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LOGC. In the last year negative earnings were reported.
Also next year LOGC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -1.72

4.3 Compensation for Growth

A more expensive valuation may be justified as LOGC's earnings are expected to grow with 12.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.97%
EPS Next 3Y12.15%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LOGC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CONTEXTLOGIC INC - A

NASDAQ:LOGC (5/17/2024, 7:11:08 PM)

After market: 5.3803 -0.1 (-1.82%)

5.48

-0.05 (-0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap180.64M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -68.77%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM -240.64%
PM (TTM) -246.71%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.99
Quick Ratio 1.99
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)31.36%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y34.6%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)174.32%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y